ClinicalTrials.Veeva

Menu

The Safety and Efficiency of Stent-based Diverting Technique Versus Ileostomy in Rectal Cancer Patients

Zhejiang University logo

Zhejiang University

Status

Enrolling

Conditions

Rectal Neoplasms

Treatments

Procedure: Stent-based Diverting Technique

Study type

Interventional

Funder types

Other

Identifiers

NCT06204497
SRRSH.SDT

Details and patient eligibility

About

The goal of this clinical trial is to evaluate the safety and efficiency of stent-based tiverting technique (SDT) versus ileostomy in rectal cancer patients. After the removal of the rectal tumor, participants who are at high risk for anastomotic leakage will either undergo SDT or ileostomies. Researchers will compare SDT to see if SDT could help patients save hospital stays, lower medical costs, and enhance their quality of life, and not alternatively avoid defunction stoma.

Full description

In patients with rectal cancer who have a high risk of anastomotic leakage, we aim to compare the safety and effectiveness of SDT versus ileostomy in this study. The primary endpoint of the study was severe complications that occurred within 90 days of the surgery. The secondary endpoints included total complications, the incidence of coloanal anastomotic leakage (Grade B/C), postoperative hospital stay and cost, and postoperative quality of life evaluation.

Enrollment

570 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Rectal adenocarcinoma confirmed pathologically.
  2. Rectal cancer patients with high-risk of anastomotic leakage(AL).
  3. Age from over 18 to under 80 years.
  4. Performance status of 0/1 on ECOG (Eastern Cooperative Oncology Group) scale.
  5. ASA (American Society of Anesthesiology) score class I, II, or III.
  6. Written informed consent.

Definition of high-risk of AL (one of them):

  1. Preoperative body mass index (BMI) ≥30 kg/m2;
  2. Long-term use of glucocorticoids before surgery (≥2 weeks);
  3. Poor general condition: Preoperative serum albumin was less than 30.0g/L after supportive treatment; or Preoperative renal replacement therapy (blood purification/hemodialysis) is required; or diabetes;
  4. Preoperative neoadjuvant radiotherapy;
  5. Distance between tumor and anal anus (baseline MRI) ≤7cm
  6. The number of stapler used to cut the rectum during the operation ≥3; or the defect of anastomosis is observed; or Intraoperative leak test was positive.

Exclusion criteria

  1. History of previous rectectomy, except endoscopic mucosal resection or endoscopic submucosal dissection.
  2. Familial Adenomatosis Polyposis Coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), active Crohn's disease or active colitis ulcerosa.
  3. History of unstable angina, myocardial infarction, cerebrovascular accident within the past six months.
  4. Groups who are particularly vulnerable include those who suffer from mental disease, cognitive impairment, severe illness, adolescents, illiterates, women during pregnancy or breast-feeding, etc.
  5. Patients with severe complications who do not tolerate surgery or need emergency surgery due to complication (bleeding, obstruction or perforation)
  6. Unable ot radical resection, or underwent Miles or Hartmann or TaTME procedure, or requirement of simultaneous surgery for other disease (except the gallblader or appendix due to benign lesion).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

570 participants in 2 patient groups

Stent-based Diverting Technique
Experimental group
Description:
For Stent-based Diverting Technique, the small intestine measuring 15 cm from the ileocecal junction was pulled out through the median incision in the lower abdomen. After a length-wise incision was established in the mesenteric margin of the small intestine, the degradable stent was implanted, and the intestine was sutured. Then, the stent was held in place using an external tie around the bowel. Next, a mushroom-like tube (28 Fr) was placed into the intestine proximal (5-10 cm) to the aforementioned stent. The other side of the mushroom-like tube was inserted through the right lower abdominal wall and connected with a drainage bag. An abdominal drainage tube, or an anal tube, if necessary, was inserted in the proper location prior to the closure of the incision and the abdominal cavity. Abdominal X-ray was routinely performed every week to detect stent degradation, and the mushroom-like tube (28 Fr) was removed two days after stent degradation.
Treatment:
Procedure: Stent-based Diverting Technique
Ileostomy
Active Comparator group
Description:
There will be an ileostomy for the control group. An incision with a diameter of 2 cm will be performed in the lower abdomen, and layers will be separated into the abdominal cavity. The intestine, 20cm to the ileocecal juction under laparoscopic vision, will be pulled out. The anterior sheath of the rectus abdominis and the serous layer of the intestine will be sutured with an absorbable line. Then, the middle point of the mesangial margin of the intestine will be transected, and the intestine will be fixed on the skin. No volvulus or angular formation of the intestine should be confirmed laparoscopically.
Treatment:
Procedure: Stent-based Diverting Technique

Trial contacts and locations

20

Loading...

Central trial contact

Yifan Tong, PhD; Lingfei Li, bachelor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems